ICU Medical (ICUI) Set to Announce Earnings on Tuesday

ICU Medical (NASDAQ:ICUI) will issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.84 per share for the quarter. ICU Medical has set its FY24 guidance at $4.40-5.10 EPS and its FY 2024 guidance at 4.400-5.100 EPS.Parties interested in participating in the company’s conference call can do so using this link.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $0.85 by $0.39. ICU Medical had a positive return on equity of 6.35% and a negative net margin of 1.31%. The business had revenue of $587.86 million during the quarter, compared to analyst estimates of $564.77 million. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Stock Performance

Shares of ICUI stock opened at $99.99 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.06 and a current ratio of 2.53. The company’s fifty day moving average price is $100.98 and its 200-day moving average price is $97.19. ICU Medical has a 12 month low of $78.28 and a 12 month high of $212.43.

Insider Transactions at ICU Medical

In related news, VP Daniel Woolson sold 791 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $98.27, for a total transaction of $77,731.57. Following the sale, the vice president now directly owns 13,980 shares of the company’s stock, valued at approximately $1,373,814.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Daniel Woolson sold 791 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $98.27, for a total value of $77,731.57. Following the completion of the transaction, the vice president now directly owns 13,980 shares in the company, valued at approximately $1,373,814.60. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director George A. Lopez sold 7,978 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $101.87, for a total value of $812,718.86. Following the sale, the director now owns 877,343 shares in the company, valued at $89,374,931.41. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,262 shares of company stock valued at $2,545,532. Insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

Separately, KeyCorp upped their price objective on shares of ICU Medical from $134.00 to $136.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and a consensus target price of $123.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.